BioConvergence Innovation
An Emerging Paradigm
BioConvergence Innovation is a paradigm where discovery and technology creation occur at the intersection of biotechnology, chemistry, nanotechnology, the physical and information sciences. Firms and researchers will cross the boundaries between these disciplines to create technological value--finding solutions to address health, environmental and energy challenges across markets. In parallel will be the emergence of new models of collaboration to enable knowledge creation and knowledge dissemination. Central to BioConvergence Innovation will be a determination of the common value of knowledge versus the private value of knowledge across the associated disciplines--with the goal of advancing and commercializing technology. (Allarakhia, 2011)
Convergence Innovation: Nanotechnology Development at the Intersection of Disciplines, Organizations and Products
August 12 2011
Convergence in nanotechnology can be considered at three levels namely—convergence in the sources of knowledge for research, convergence in organizational forms to enable technology development, and convergence at the product level with the embodiment of knowledge in complementary products. At each level of convergence, there are several complexities that either impact the management of stakeholder interaction or the management of the knowledge based assets generated through such interactions.
Read More...
Managing knowledge assets under conditions of radical change: The case of the pharmaceutical industry
June 2nd 2011
A major paradigm change has occurred as to where and how knowledge is generated and protected that is challenging the industry. The pharmaceutical industry traditionally dominated by large firms who relied on their own chemical research, is now more and more faced with a new drug discovery reality with knowledge more often than not developed outside of the walls of large pharmaceutical companies. Since the completion of the Human Genome Project, new technology in this industry is often generated at the intersection between bio-pharmacology, chemistry, nanotechnology, and computational sciences. To manage these technological complexities, the industry has embraced the concept of research consortia as a model of knowledge generation if not proactive knowledge management in the bioconvergence paradigm.
Here we see the interaction between models of open innovation and technological convergence.
Read more...
